Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.

Laboratoire de Bactériologie EA 3671, Université Victor Segalen Bordeaux 2 and CHU de Bordeaux, Bordeaux cedex, France.
Journal of Antimicrobial Chemotherapy (Impact Factor: 5.34). 06/2009; 64(1):52-8. DOI: 10.1093/jac/dkp160
Source: PubMed

ABSTRACT Mycoplasma pneumoniae is a common aetiological agent of community-acquired respiratory tract infections for which macrolides are the treatment of choice. In France, only two macrolide-resistant isolates were reported in 1999. In contrast, several recent data reported that macrolide-resistant M. pneumoniae isolates have been spreading since 2000 in Japan. Mutations A2058G (Escherichia coli numbering), A2058C, A2059G, A2062G, C2611A and C2611G in domain V of the 23S rRNA gene were associated in vivo or in vitro with this resistance. The aim of this study was to determine whether macrolide resistance of M. pneumoniae is emerging in France.
We developed a duplex real-time PCR for the detection of the six 23S rRNA mutations associated with macrolide resistance in M. pneumoniae and a simplex real-time PCR for the identification of the A2058G mutation, the most common one. Both methods rely on fluorescence resonance energy transfer coupled to melting curve analysis and are directly applicable to clinical samples. The duplex real-time PCR assay, first validated on 40 genetically characterized M. pneumoniae strains, was then applied directly on 248 French respiratory tract clinical samples.
Among M. pneumoniae-positive specimens collected before 2005, no macrolide-resistant M. pneumoniae isolate was detected. In contrast, among 51 samples collected between 2005 and 2007, five (9.8%) yielded a resistant genotype, suggesting a recent increase in macrolide-resistant M. pneumoniae isolates in France.
The epidemiological monitoring of macrolide resistance in this species has become necessary in France and Europe, and will be made easier by using these PCR assays.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In Korea, Mycoplasma pneumoniae was detected in 255/2,089 respiratory specimens collected during 2000-2011; 80 isolates carried 23S rRNA gene mutations, and 69/123 culture-positive samples with the mutation were resistant to 5 macrolides. During 2000-2011, prevalence of the mutation increased substantially. These findings have critical implications for the treatment of children with mycoplasma pneumonia.
    Emerging Infectious Diseases 08/2013; 19(8):1281-4. · 6.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mycoplasma and Ureaplasma species are well-known human pathogens responsible for a broad array of inflammatory conditions involving the respiratory and urogenital tracts of neonates, children, and adults. Greater attention is being given to these organisms in diagnostic microbiology, largely as a result of improved methods for their laboratory detection, made possible by powerful molecular-based techniques that can be used for primary detection in clinical specimens. For slow-growing species, such as Mycoplasma pneumoniae and Mycoplasma genitalium, molecular-based detection is the only practical means for rapid microbiological diagnosis. Most molecular-based methods used for detection and characterization of conventional bacteria have been applied to these organisms. A complete genome sequence is available for one or more strains of all of the important human pathogens in the Mycoplasma and Ureaplasma genera. Information gained from genome analyses and improvements in efficiency of DNA sequencing are expected to significantly advance the field of molecular detection and genotyping during the next few years. This review provides a summary and critical review of methods suitable for detection and characterization of mycoplasmas and ureaplasmas of humans, with emphasis on molecular genotypic techniques.
    The Journal of molecular diagnostics: JMD 07/2012; 14(5):437-50. · 3.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of macrolide-resistant (MR) Mycoplasma pneumoniae has become much more apparent in the past decade. We investigated differences in the therapeutic efficacy of macrolides, minocycline, and tosufloxacin against MR M. pneumoniae. A total of 188 children with M. pneumoniae pneumonia confirmed by culture and polymerase chain reaction (PCR) were analyzed. Of these, 150 patients had a MR gene; 134 patients had an A to G mutation at position 2,063 of M. pneumoniae 23S ribosomal RNA domain V. Azithromycin (n = 27), clarithromycin (n = 23), tosufloxacin (n = 62), or minocycline (n = 38) were used for definitive treatment of patients with MR M. pneumoniae. Defervescence within 48 hours after initiation of antibiotics was observed in 41% of patients in the azithromycin group, 48% of the clarithromycin group, 69% of the tosufloxacin group, and 87% of the minocycline group. The average days of fever after administration of antibiotic treatment was shorter in the minocycline and tosufloxacin groups than in the macrolide groups. The decrease in M. pneumoniae burden, as estimated by DNA copies, after 48 to 96 hours' treatment was more rapid in patients receiving minocycline (p = 0.016) than in those receiving tosufloxacin (p = 0.049), azithromycin (p = 0.273) or clarithromycin (p = 0.107). We found that the clinical and bacteriological efficacy of macrolides for treating cases of MR M. pneumoniae was low. Our results indicated that minocycline rather than tosufloxacin can be considered as the first choice drug for the treatment of M. pneumoniae pneumonia in children aged ≥8 years.
    Antimicrobial Agents and Chemotherapy 03/2013; · 4.57 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014